At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
HLD200 (methylphenidate hydrochloride)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining the Pharmacokinetic Effects of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With ADHD
Ironshore Pharmaceuticals and Development, Inc·interventional·Posted Jul 24, 2013·Updated Dec 23, 2021
In Brief
A Phase 2 clinical trial evaluating HLD200 (methylphenidate hydrochloride) for Attention-Deficit Hyperactivity Disorder. Completed, enrolled 29 participants across 1 site.
Detailed Summary
This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention-Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartAug 2013
Primary CompletionOct 2013
TodayJul 2026
First PostedJul 24, 2013
Enrollment StartAug 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.9 years ago
Interventions
HLD200 (methylphenidate hydrochloride)drug